GuideMia Biotechnology (Shanghai) Co., Ltd.

GuideMia Biotechnology (Shanghai) Co. , Ltd. is a company specializing in digital dentistry solutions, delivering innovative products that enhance dental implant planning and orthodontic treatments. Founded in 2016 in Shanghai, China, GuideMia Biotechnology focuses on developing digital solutions for the dental industry.

The company has not undergone any significant changes in its operational strategy and does not have known subsidiaries. It has one notable funding round where it raised CNY 10 million in Angel funding from CASH Capital on January 13, 2018, totaling CNY 10 million raised to date. Fei Gao serves as both the Founder and CEO of the company. GuideMia Technologies Inc.

specializes in the development of digital dentistry solutions, focusing on innovative software and products that enhance dental implant planning, surgical guides, and orthodontic treatment. Their core offerings include the GuideMia Implant System, which facilitates both simple and complex dental procedures, such as immediate extractions and full arch reconstructions. Additionally, GuideMia provides the Ortho+ software, a comprehensive orthodontic treatment planning solution integrating CBCT and optical scans, designed for both clear aligners and direct bonding guides. Their products serve a diverse client base, including dental professionals and laboratories across 15 countries, primarily in North America, Europe, and parts of Asia.

By addressing critical challenges within the dental industry, GuideMia aims to improve treatment efficacy, safety, and operational efficiencies for its end users. GuideMia operates a multifaceted revenue model, encompassing direct sales, subscriptions, and transactional services. The company offers a lifetime license for its flagship GuideMia Implant Master Series at a price of CNY 2,500, along with various export credit packages that facilitate the use of their software for case management and treatment planning. Additionally, the GuideMia OrthoClic software operates on a monthly subscription basis, priced at CNY 19, which provides users with essential features for quick treatment planning.

By structuring transactions around licensing fees and subscription models, GuideMia maintains a direct-to-consumer approach, primarily targeting dental professionals and practices that require advanced digital solutions in their workflows. Such offerings emphasize not only the company's commitment to innovation in dental technology but also its strategic positioning within the marketplace. In January 2018, GuideMia Biotechnology (Shanghai) Co. , Ltd.

raised CNY 10 million in Angel funding to support its growth initiatives. The company plans to introduce new products, including enhancements to its GuideMia Implant System and new features for the Ortho+ software, aiming for launch in late 2023. Additionally, GuideMia is looking to expand its presence into new markets in Southeast Asia and Australia by 2024, leveraging its recent funding to facilitate this growth.